KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Aquestive Therapeutics (AQST) Receivables - Net (2017 - 2025)

Aquestive Therapeutics has reported Receivables - Net over the past 9 years, most recently at $17.8 million for Q4 2025.

  • Quarterly results put Receivables - Net at $17.8 million for Q4 2025, up 141.87% from a year ago — trailing twelve months through Dec 2025 was $17.8 million (up 141.87% YoY), and the annual figure for FY2025 was $17.8 million, up 141.87%.
  • Receivables - Net for Q4 2025 was $17.8 million at Aquestive Therapeutics, up from $11.8 million in the prior quarter.
  • Over the last five years, Receivables - Net for AQST hit a ceiling of $19.9 million in Q1 2022 and a floor of $4.7 million in Q4 2022.
  • Median Receivables - Net over the past 5 years was $9.1 million (2021), compared with a mean of $10.6 million.
  • Biggest five-year swings in Receivables - Net: soared 144.78% in 2022 and later crashed 62.05% in 2023.
  • Aquestive Therapeutics' Receivables - Net stood at $9.7 million in 2021, then tumbled by 51.39% to $4.7 million in 2022, then skyrocketed by 80.08% to $8.5 million in 2023, then fell by 13.3% to $7.3 million in 2024, then skyrocketed by 141.87% to $17.8 million in 2025.
  • The last three reported values for Receivables - Net were $17.8 million (Q4 2025), $11.8 million (Q3 2025), and $11.9 million (Q2 2025) per Business Quant data.